We aim to address patient needs through transformational innovation. With a focus on key therapeutic areas like immunology, we bring together the best science, technology and next-generation biological capabilities from inside and outside our company.
We combine deep disease expertise and multiple drug modalities with a goal of reducing risk and speeding time for treatments to reach patients. Our portfolio is grounded in a long history of research into small molecules. We have a unique approach in developing novel biological medicines, and groundbreaking research capabilities in cell therapy.
We believe in the power of partnerships.
Our ambition is to be a trusted partner to the patient community. We are committed to collaborating with patients across the lifecycle of medicines.
We apply and invest our breadth of resources in new technologies and programs with the potential and goal to radically improve treatment paradigms.
Our purpose is to create impact together with patients worldwide. By 2028, we aim to add more years of life and quality of life for patients. We aim to develop pivotal stage therapies for patients, with patients and the healthcare community. We aim to be a diverse, equitable, inclusive, and trusted organization. Plus, we aim to be climate neutral, and to provide access to our medicines across all contintents.
The UK and Ireland operation of Galapagos was set up in 2020, aiming to offer patients in the UK and Ireland with treatment options for unmet medical needs in therapeutic areas like immunology. At Galapagos, we are proud to be among a rare group of fully integrated biotech companies advancing early research to be a marketed medicine. Today we are building on our foundation and continually adding to our pipeline of innovations. Through ongoing development and through discovery and acquisition, we aim to make a positive impact on patients living with life changing diseases.
”Galapagos Health is the portal for healthcare professionals in the field of Rheumatoid Arthritis and Ulcerative Colitis, offering relevant medical information, expert insights and information on events in these fields.”
Paul Stoffels, CEO
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
GB--FIL-202308-00005 | Date of preparation: October 2023
Adverse events should be reported.
For Great Britain, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For the Republic of Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 00800 7878 1345.
Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
© 2022 Galapagos NV. All rights reserved.
GB-IBD-FIL-202208-00005 |
Date of preparation: October 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
© 2022 Galapagos NV. All rights reserved.
GB-IBD-FIL-202208-00005 |
Date of preparation: October 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
© Copyright 2021 Galapagos NV
This link will take you away from the Galapagos website and you will be re-directed to a non-Galapagos website. Galapagos does not accept liability for sites controlled by third-parties.
*By choosing the "Healthcare Professional" option, you affirm your status as a healthcare professional in the UK and Ireland and acknowledge that you will receive promotional information pertaining to prescription-only medicines.
